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Purpose: To characterize the incidence, outcomes, and predictors 
of left ventricular (LV) thrombus by using sequential car-
diac magnetic resonance (MR) imaging after ST-segment–
elevation myocardial infarction (STEMI).
Materials and 
Methods:
Written informed consent was obtained from all patients, 
and the study protocol was approved by the committee on 
human research. In a cohort of 772 patients with STEMI, 
392 (mean age, 58 years; range, 24–89 years) were ret-
rospectively selected who were studied with cardiac MR 
imaging at 1 week and 6 months. Cardiac MR imaging 
guided the initiation and withdrawal of anticoagulants. Pa-
tients with LV thrombus at 6 months were restudied at 
1 year. For predicting the occurrence of LV thrombus, a 
multiple regression model was applied.
Results: LV thrombus was detected in 27 of 392 patients (7%): 18 
(5%) at 1 week and nine (2%) at 6 months. LV thrombus 
resolved in 22 of 25 patients (88%) restudied within the 
first year. During a mean follow-up of 181 weeks 6 168, 
patients with LV thrombus displayed a very low rate of 
stroke (0%), peripheral embolism (0%), and severe hem-
orrhage (n = 1, 3.7%). LV ejection fraction (LVEF) less 
than 50% (P , .001) and anterior infarction (P = .008) 
independently helped predict LV thrombus. The incidence 
of LV thrombus was as follows: (a) nonanterior infarction, 
LVEF 50% or greater (one of 135, 1%); (b) nonanterior 
infarction, LVEF less than 50% (one of 50, 2%); (c) ante-
rior infarction, LVEF 50% or greater (two of 92, 2%); and 
(d) anterior infarction, LVEF less than 50% (23 of 115, 
20%) (P , .001 for the trend).
Conclusion: Cardiac MR imaging contributes information for the diag-
nosis and therapy of LV thrombus after STEMI. Patients 
with simultaneous anterior infarction and LVEF less than 
50% are at highest risk.
q RSNA, 2017
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severe unstable condition during admis-
sion or within the first 6 months after 
STEMI; and patients with any contrain-
dications to cardiac MR imaging were 
not considered for participation. From 
2002 to 2014, we enrolled 772 patients 
with their first STEMI and, of them, 392 
were retrospectively selected to be in-
cluded in the study group. The flowchart 
of patients is displayed in Figure 1.
Clinical and angiographic character-
istics were prospectively registered in all 
cases at admission. The percutaneous 
coronary intervention technique was left 
at the discretion of the interventional 
operator. Thrombolysis in Myocar-
dial Infarction flow grade in the culprit 
artery (before and after percutaneous 
coronary intervention) was analyzed in 
all patients. Further details on patient 
characteristics are reflected in Table 1.
Patients were treated both in hos-
pital and after discharge by a specific 
STEMI unit, and current recommen-
dations were strictly followed (8,10). 
Baseline characteristics and therapies 
prescribed in the whole study group 
and in patients with and without LV 
thrombus are listed in Table 1 and 
Tables E1 and E2 (online).
Patients in whom LV thrombus was 
detected at 1-week cardiac MR imaging 
in patients with LV thrombus and with-
drawal when this finding resolves at 
subsequent cardiac MR imaging results 
in a low rate of complications, and (c) a 
simple score can be created to predict 
the occurrence of LV thrombus within 
the first 6 months after STEMI.
Our objectives were to characterize 
the incidence, outcomes, and predic-
tors of LV thrombus using sequential 
cardiac MR imaging after STEMI.
Materials and Methods
Patients
This study stems from a large prospective 
ongoing registry of STEMI patients per-
formed in a tertiary university hospital. 
All patients gave written informed con-
sent. The study protocol was approved 
by the local ethics committee on human 
research and conforms to the guidelines 
of the 1975 Declaration of Helsinki.
Patients were considered to be in-
cluded in the study group if they were 
admitted for a first STEMI defined by 
following current definitions (10), were 
treated with percutaneous coronary in-
tervention, and underwent cardiac MR 
imaging 1 week and 6 months after in-
farction. Nonrevascularized patients; 
those revascularized more than 12 hours 
after the onset of chest pain; patients 
with a documented history of previous 
myocardial infarction; those who had 





BARC = Bleeding Academic Research Consortium
LGE = late gadolinium enhancement
LV = left ventricle
LVEF = LV ejection fraction
STEMI = ST-segment–elevation myocardial infarction
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Advances in Knowledge
 n By using sequential cardiac MR 
imaging, left ventricular (LV) 
thrombus was detected in 27 of 
392 patients (7%) within the first 
6 months after reperfused ST-
segment–elevation myocardial 
infarction (STEMI).
 n A strategy of anticoagulation 
therapy guided by cardiac MR 
imaging solved LV thrombus in 22 
of 25 patients (88%) restudied 
within the first year and resulted 
in a low incidence (one of 27, 
3.7%) of stroke, peripheral embo-
lism, and hemorrhagic events.
 n Patients with simultaneous ante-
rior STEMI and LV ejection frac-
tion (LVEF) less than 50% at 1 
week were at highest risk of LV 
thrombus (23 of 115, 20%).
Implications for Patient Care
 n Cardiac MR imaging performed 
sequentially after a first STEMI 
treated with percutaneous coro-
nary intervention is effective to 
properly detect LV thrombus.
 n The use of anticoagulants guided 
by cardiac MR imaging effectively 
resolves LV thrombus in patients 
restudied within the first year.
 n Due to the high incidence of LV 
thrombus in patients with simul-
taneous anterior STEMI and 
LVEF less than 50% at 1 week, 
this is the subset that can benefit 
most from sequential cardiac MR 
imaging.
A substantial number of cases with left ventricular (LV) thrombus go undetected with echocardi-
ography (1–4). Although late gadolin-
ium enhancement (LGE) with cardiac 
magnetic resonance (MR) imaging has 
been demonstrated to be the reference 
technique to detect LV thrombus soon 
after ST-segment–elevation myocardial 
infarction (STEMI) (1–7), data on the 
incidence and outcomes of this finding 
within the months following reperfu-
sion as derived from cardiac MR imag-
ing are scarce.
Recent recommendations consider it 
reasonable to use anticoagulants to treat 
patients with STEMI with LV thrombus 
(8–10). Evidence for these recommen-
dations relies mainly on series analyzed 
with echocardiography. Thus, there is a 
need to know the outcomes of STEMI 
patients with LV thrombus in whom an-
ticoagulant therapy was guided by car-
diac MR imaging as well as to identify 
the subset that can benefit most from 
this technique to properly diagnose and 
follow up this finding.
We hypothesize that (a) sequential 
cardiac MR imaging permits an accurate 
definition of the incidence of LV throm-
bus within the first 6 months after STE-
MI, (b) a cardiac MR-guided strategy 
based on the initiation of anticoagulants 
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multisection and segmented turbo spin 
echo) as areas with high T2 signal 
intensity (. 2 standard deviations in 
comparison with a remote noninfarct-
ed area in the same section) and was 
visually revised and expressed as per-
centage of LV mass. Myocardial salvage 
index was calculated by subtracting 
the mass of the infarcted myocardium 
from myocardium showing edema and 
was expressed as percentage of LV 
mass with myocardial edema.
The operator who subsequently 
performed the quantification of all car-
diac MR studies (J.G.) and one of the 
operators who acquired the cardiac MR 
images (J.V.M.) analyzed separately in 
all the studies the presence or absence 
of LV thrombus. Disagreement took 
place in three cases (0.8%) at the 1st 
week and in two (0.5%) cases at 6th 
months and was solved by consensus. 
The inter- and intraobserver variability 
for the calculation of the rest of cardiac 
MR indexes used in the present study 
in our laboratory has been previously 
reported and is less than 5% (11).
Further details on the technical 
aspects of cardiac MR acquisition and 
sequences can be consulted in the Ap-
pendix E1 (online).
End Points
The objective of the present study was 
to analyze in a prospective series of 
patients with a first STEMI reperfused 
within the first 12 hours after onset of 
chest pain, without any contraindica-
tions to cardiac MR imaging, and se-
quentially examined with cardiac MR 
imaging 1 week and 6 months after in-
farction (a) the incidence of LV throm-
bus, (b) the outcome of LV thrombus 
by using cardiac MR imaging to guide 
the anticoagulation therapy, and (c) 
to design a simple score to identify 
those patients who are at highest risk 
of developing LV thrombus within the 
first 6 months after STEMI and conse-
quently can benefit most from a tighter 
follow-up.
The outcomes of patients in terms 
of the occurrence of stroke, peripheral 
embolism, and hemorrhage greater than 
Bleeding Academic Research Consortium 
(BARC) type 2 (any overt actionable sign 
LV thrombus was defined at LGE by 
using a segmented inversion-recovery 
steady-state free-precession sequence. 
LV thrombus characteristically had a 
gray etched appearance compared with 
black (viable) or white (infarcted) myo-
cardium (Fig 2), with avascular tissue 
adherent to regions with abnormal wall 
motion, protruding and clearly distin-
guishable from cardiac structures or 
technical artifacts. Similar to recent data 
(2,3), routine nonenhanced echocardi-
ography performed during admission 
yielded limited sensitivity for detection 
of LV thrombus at LGE (10 of 27, 37%).
LV ejection fraction (LVEF), LV end-
diastolic volume index, LV end-systolic 
volume index, and LV mass index were 
calculated by means of manual planim-
etry of endocardial and epicardial bor-
ders in short-axis view cine images.
Areas showing LGE (. 2 standard 
deviations in comparison with a remote 
noninfarcted area in the same section) 
were visually revised and quantified 
with manual planimetry. Infarct size 
was assessed as the percentage of LV 
mass showing LGE. Microvascular ob-
struction was quantified by manual pla-
nimetry and defined as the percentage 
of LV mass showing a lack of contrast 
material uptake in the core of tissue 
showing LGE.
Myocardial edema was defined 
in T2 sequences (half-Fourier acqui-
sition single-shot turbo spin-echo 
were submitted to the hematology de-
partment, and anticoagulant therapy 
with the vitamin K antagonist acenocou-
marol was initiated to achieve a target in-
ternational normalized ratio of 2.0–3.0. 
At 6 months, patients were re-evaluated 
and oral anticoagulation was maintained 
(if LV thrombus persisted), suspended 
(if LV thrombus had vanished), or start-
ed (in patients with newly detected LV 
thrombus).
Cardiac MR Imaging
All patients included in the study group 
were examined with a 1.5-T MR System 
(Sonata Magnetom; Siemens, Erlan-
gen, Germany) at 1 week (7 days 6 2 
[standard deviation] ) and 6 months 
(183 days 6 21) after STEMI according 
to our previously validated study pro-
tocol (11). Eleven of 13 patients with 
LV thrombus at 6-month cardiac MR 
underwent a third cardiac MR study 1 
year after STEMI (371 days 6 31).
All studies were performed by two 
cardiologists (J.V.M. and M.P.L.L., 
with 15 years of experience) special-
ized in cardiac MR imaging and quan-
tified offline by a third operator (J.G., 
with 3 years of experience) blinded 
to all patient data using customized 
software (QMASS MR, 6.1.5; Medis, 
Leiden, the Netherlands). Cardiac MR 
data were prospectively recorded and 
immediately included in the registry 
database.
Figure 1
Figure 1: Flowchart of patients and reasons for exclusion.
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with the respective 95% confidence in-
tervals were computed. Variables with a 
two-tailed P value , .05 were included 
in the final model. Infarct location (ante-
rior vs nonanterior) and LVEF (as a con-
tinuous variable) were the independent 
predictors. The predictive power of this 
model was determined by using the area 
under the receiver operating character-
istics curve (estimated with the c-statist 
test). Then a simpler (from a clinical per-
spective) score was proposed by dichot-
omizing patients according to infarct lo-
cation (anterior vs nonanterior) and the 
state of LVEF (preserved vs depressed). 
LVEF was dichotomized via univariate 
receiver operating characteristics tech-
niques. Once the best cut-off value of 
LVEF at 1-week cardiac MR imaging 
(depressed if , 50%) for the prediction 
of LV thrombus was obtained, patients 
were categorized as having (a) nonante-
rior infarction, preserved LVEF; (b) non-
anterior infarction, depressed LVEF; (c) 
anterior infarction, preserved LVEF; and 
(d) anterior infarction, depressed LVEF. 
The in-sample predictive value of these 
categories to predict LV thrombus at the 
univariate analysis was assessed.
Statistical significance was consid-
ered for a two-tailed P , .05. The SPSS 
statistical package (version 21.0; SPSS, 
Chicago, Ill) was used.
Results
Among 772 patients with STEMI con-
secutively admitted to our institution 
from January 2002 to December 2014 
and reperfused within the first 12 
hours after chest pain onset, the final 
study group comprised 392 patients. 
The complete flowchart of patients is 
displayed in Figure 1, and the baseline 
characteristics are listed in Table 1.
Incidence and Outcomes of LV Thrombus
Overall, LV thrombus was detected at 
1 week in 28 of 574 patients (5%) who 
underwent 1-week cardiac MR imaging. 
Among 392 patients included in the fi-
nal study group, LV thrombus occurred 
in 27 patients (7%) within the first 6 
months after STEMI, 18 (67%) patients 
at 1 week, and nine (33%) patients at 6 
months (Fig 3).
compared by using the Mann-Whitney 
U test. Group percentages were com-
pared by using the x2 test or the Fisher 
exact test, where appropriate. P for the 
trend was used to compare more than 
two percentages. The association of LV 
thrombus with time to stroke, peripheral 
embolism, or hemorrhage greater than 
BARC type 2 was assessed by using Ka-
plan-Meier curves and the log-rank test.
For predicting the occurrence of LV 
thrombus, forward stepwise multiple bi-
nary logistic regression was used after 
adjustment according to baseline and 
cardiac MR variables, yielding a P value 
, .2 at univariate analyses. Odds ratios 
of hemorrhage requiring attention by a 
health care professional, prompting eval-
uation, leading to hospitalization, and 
fatal bleedings) (12) were recorded. To 
adjudicate an event, consensus between 
two cardiologists was required.
Statistical Analysis
Data were tested for normal distribution 
by using the Kolmogorov-Smirnov test. 
Continuous normally distributed data 
were expressed as the mean 6 standard 
deviation and compared by using the 
unpaired samples Student t test. Non-
parametric data were expressed as the 
median with the interquartile range and 
Table 1
Baseline Characteristics of the Whole Study Group and Patients with and without LV 
Thrombus within the First 6 Months after STEMI
Characteristic All Patients
Patients with  
LV Thrombus 
Patients without  
LV Thrombus P Value
No. of patients 392 27 365 …
Age (y)* 58 6 12 58 6 13 58 6 12 .9
Male sex 321 (82) 23 (85) 298 (82) .6
Diabetes mellitus 73 (19) 6 (22) 67 (18) .8
Hypertension 181 (46) 10 (37) 171 (47) .3
Hypercholesterolemia 170 (44) 12 (44) 158 (43) .9
Smoker 235 (60) 16 (59) 219 (60) .9
Heart rate (beats per min)* 79 6 20 80 6 18 79 6 20 .7
Systolic pressure (mm Hg)* 131 6 29 132 6 28 131 6 29 .8
Killip class .1
 I 344 (88) 322 (88) 22 (82) …
 II 37 (9) 3 (11) 34 (9) …
 III 3 (1) 0 (0) 3 (1) …
 IV 8 (2) 2 (7) 6 (2) …
Time to reperfusion (min)† 195 (1342311) 225 (1302420) 190 (1352300) .02
ST-segment resolution (%)† 81 (592100) 68 (42283) 81 (602100) .01
Anterior infarction 207 (53) 25 (93) 182 (50) .001
Multivessel disease 101 (26) 3 (11) 98 (27) .3
TIMI flow grade before PCI .2
 0 177 (45) 17 (63) 160 (44) …
 1 23 (6) 0 (0) 23 (6) …
 2 42 (11) 1 (4) 41 (11) …
 3 149 (38) 9 (33) 140 (38) …
TIMI flow grade after PCI .1
 0 8 (2) 0 (0) 8 (2) …
 1 1 (0.3) 1 (4) 0 (0) …
 2 24 (6) 5 (19) 19 (5) …
 3 358 (92) 21 (78) 337 (93) …
Note.—Unless otherwise indicated, data are percentages with the number of patients in parentheses. PCI = percutaneous 
coronary intervention, TIMI = Thrombolysis in Myocardial Infarction.
* Data are means 6 standard deviation.
† Data are medians with 25th and 75th percentiles in parentheses.
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A newly detected LV thrombus ap-
peared in nine of 392 patients (2%) at 
6-month cardiac MR imaging. Overall, 
13 of 392 patients (3%) displayed LV 
thrombus at 6-month cardiac MR imag-
ing: in four of them it was already de-
tected at 1 week and in nine it was newly 
identified at 6 months. Oral anticoagula-
tion was maintained in the former and 
initiated in the latter (Fig 3).
Of 13 patients with LV thrombus at 
6-month cardiac MR imaging, 11 were 
re-examined with cardiac MR at 1 year. 
Two patients were excluded (one died 
of refractory heart failure and one had 
implantable cardioverter defibrillator). 
Among 11 patients with LV thrombus at 
6-month cardiac MR imaging, the throm-
bus vanished in eight (73%) and persist-
ed in three (27%) at 1 year (Fig 3).
Thus, LV thrombus disappeared in 
22 of 25 patients (88%) in whom this 
finding had been detected at cardiac 
MR imaging within the first 6 months 
after STEMI and had been re-examined 
at 1 year (Fig 3).
During a mean follow-up of 181 
weeks 6 168, the occurrence of stroke 
(n = 0), peripheral embolism (n = 0), 
and hemorrhage greater than BARC 
type 2 (n = 1, 3.7%) was very low in 
those 27 patients with LV thrombus 
detected within the first 6 months and 
with anticoagulation therapy guided by 
cardiac MR results. The rates of stroke, 
peripheral embolism, and hemorrhage 
greater than BARC type 2 in patients 
with and without LV thrombus are 
shown in Table 2.
Predictors of LV Thrombus
Baseline characteristics and cardiac 
MR data associated with the presence 
of LV thrombus are depicted in Tables 
1 and 3, respectively.
At the multivariate analysis, baseline 
variables and cardiac MR data showing 
an association with LV thrombus (P , 
.2 at univariate analyses) were tested. 
All variables tested at the multivariate 
analysis and their respective odds ra-
tios and 95% confidence intervals are 
displayed in Table 4. The independent 
predictors of LV thrombus were ante-
rior infarction (odds ratio, 7.38 [95% 
confidence interval: 1.67, 32.65]; P = 
persistent LV thrombus at 6-month 
cardiac MR imaging (n = 4) had ante-
rior infarction and displayed a nonsig-
nificant tendency toward more severe 
structural abnormalities at 1-week car-
diac MR imaging compared with those 
patients (n = 14) in whom LV throm-
bus had vanished at 6-month cardiac 
MR imaging (Appendix E1 [online], 
Table E3 [online]).
LV thrombus occurred at 1 week in 
18 patients (5%); at that moment, all 
of them initiated oral anticoagulation 
therapy. Among the 18 patients with 
LV thrombus at 1-week cardiac MR im-
aging, the LV thrombus had vanished 
in 14 (76%) and persisted in four 
(24%) at 6-month cardiac MR imag-
ing. Oral anticoagulation was stopped 
in the former (Fig 3). All patients with 
Figure 2
Figure 2: Possible dynamics of LV thrombus ( Vth) within the first 6 months after 
STEMI. Image illustrates four possible scenarios regarding the evolution of LV throm-
bus. Top row: absence of LV thrombus at 1 week and 6 months. Second row: LV 
thrombus at 1 week that vanished at 6 months. Third row: absence of LV thrombus 
at 1 week, with a newly detected thrombus at 6 months. Last row: presence of LV 
thrombus at 1 week that persisted at 6 months. Arrow = location of thrombus.
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.008) and LVEF (odds ratio, 0.94 [95% 
confidence interval: 0.90, 0.97]; P , 
.001) (Table 4). The c-statistic of this 
model was 0.82 (95% confidence inter-
val: 0.75, 0.89; P , .001).
Patients were categorized according 
to the independent predictors: infarct 
location (anterior vs nonanterior) and 
LVEF (preserved vs depressed at 1-week 
cardiac MR). Based on the receiver op-
erating characteristics curve analysis, 
LVEF less than 50% resulted to be the 
best cut-off value to predict LV thrombus.
From a clinical perspective and 
based on these two widely available var-
iables, we constructed a simple score to 
identify patients at highest risk of de-
veloping LV thrombus within the first 6 
Figure 3
Figure 3: Outcomes of LV thrombus ( VTh) within the first 6 months after STEMI. Schematic depicts dynamics of thrombus occurrence and use of anticoagulation: 
step by step (left) and summary (right). All patients were examined with cardiac MR imaging 1 week and 6 months after STEMI. One-year cardiac MR imaging was 
performed only in patients with LV thrombus at 6 months. ICD = implantable cardioverter defibrillator.
months (at 1-week and/or 6-month car-
diac MR). The percentages of patients 
with LV thrombus in the respective 
groups were (a) nonanterior infarction, 
LVEF 50% or greater: one of 135 (1%); 
(b) nonanterior infarction, LVEF less 
than 50%: one of 50 (2%); (c) anterior 
infarction, LVEF 50% or greater: two 
of 92 (2%); and (d) anterior infarction, 
LVEF less than 50%: 23 of 115 (20%) (P 
, .001 for the trend) (Fig 4). Accord-
ingly, the majority of patients with LV 
thrombus (23 of 27, 85%) displayed a 
simultaneous anterior infarction and 
LVEF less than 50%. The occurrence of 
LV thrombus at 1-week cardiac MR im-
aging in these groups was as follows: one 
of 87 (1%), zero of 98 (0%), one of 53 
(2%), and 16 of 154 (10%), respectively 
(P , .001 for the trend).
Discussion
The main findings of the present study 
were as follows: (a) In patients with re-
perfused STEMI, cardiac MR revealed 
the presence of LV thrombus in a consid-
erable number of patients (7%) within 
the first 6 months after infarction; (b) 
a strategy of anticoagulation guided by 
sequential cardiac MR succeeded in re-
solving LV thrombus within the first year 
in the majority of cases and was associ-
ated with a very low rate of stroke, pe-
ripheral embolism, and significant hem-
orrhage; (c) patients with simultaneous 
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respectively. Thus, in this scenario, car-
diac MR becomes decisive not only for 
diagnosis but also for decision making. 
In fact, in our series with LV thrombus, 
the rate of potential complications de-
rived from lack of proper anticoagula-
tion or of potential substantial side 
effects of anticoagulants was very low: 
only one case (3.7%) of hemorrhage 
greater than BARC type 2 was regis-
tered. It should be emphasized, how-
ever, that these results were derived 
from a short series of 27 patients with 
LV thrombus treated with anticoagulant 
therapy. In this setting, safety of anti-
coagulation therapy itself should be de-
termined in a large randomized study.
The presented data suggest that 
a cardiac MR-guided strategy based 
on the use of anticoagulants when LV 
thrombus is detected after STEMI and 
maintenance or withdrawal of this ther-
apy depending on the persistence or 
disappearance of LV thrombus during 
follow-up is (a) effective for solving the 
majority of LV thrombus and (b) safe 
in terms of a very low occurrence of 
stroke, peripheral embolism, and sub-
stantial hemorrhage.
Predictors of LV Thrombus after STEMI
Attending to its wide availability and ex-
cellent cost-effectiveness balance, echo-
cardiography represents the first choice 
for assessing the structural consequences 
of myocardial infarction (10). Unfortu-
nately, the accuracy of this technique for 
detecting LV thrombus is insufficient. 
When compared with LGE, transtho-
racic echocardiography performed by 
expert operators barely detected one-
third of cases with LV thrombus (2,4). 
Furthermore, in a recent study that 
compared contrast-enhanced echocardi-
ography and LGE in STEMI, almost 40% 
of LV thrombus went undetected by the 
former (3). Thus, current evidence sug-
gests that, for a correct diagnosis of LV 
thrombus, cardiac MR imaging should 
be used. Unfortunately, this technique 
is not available at all institutions, and 
indiscriminate use may unnecessarily 
increase costs of health systems. There 
is a need to identify in a simple manner 
those patients who are at highest risk of 
developing LV thrombus and in turn can 
The inclusion of patients with chronic 
heart failure and chronic ischemic heart 
disease might explain the high occur-
rence of LV thrombus in this series. The 
same group of authors (3), in a more re-
cent series of 201 STEMI patients stud-
ied with LGE, detected 17 cases with LV 
thrombus (8%) a mean of 28 days af-
ter infarction. Finally, in a group of 194 
STEMI patients treated with percutane-
ous coronary intervention and examined 
with cardiac MR imaging, Delewi et al 
(4) reported a 9% rate of LV thrombus 
1 week after infarction.
The present study constitutes the 
largest series so far focused on the oc-
currence and outcomes of LV thrombus 
after STEMI, using cardiac MR imaging 
to diagnose this finding and to guide 
anticoagulant therapy. In our large co-
hort of 392 patients treated according 
to contemporary clinical practice, the 
overall incidence of LV thrombus within 
the first 6 months after STEMI was 
7%. Substantial dynamic changes took 
place. At 1 week, 18 patients (5% of the 
whole study group) displayed LV throm-
bus; this finding vanished at 6 months 
in three-quarters of them. Moreover, 
LV thrombus was newly detected in 
nine patients (2%) at 6 months. Over-
all, LV thrombus vanished in 22 of 25 
patients (88%) with thrombus detected 
within the first 6 months and re-exam-
ined within the first year after STEMI.
This dynamic behavior mandates 
immediate modification in patient care, 
namely prescription or interruption of 
anticoagulant therapy at the moment of 
detection or resolution of LV thrombus, 
anterior STEMI and LVEF less than 50% 
were at highest risk of LV thrombus and 
represent the subset of patients who de-
serve a tight surveillance regarding the 
occurrence of LV thrombus.
Incidence and Outcomes of LV Thrombus
An adequate detection of LV throm-
bus after STEMI brings about relevant 
implications on patient care. Although 
randomized trials addressing this topic 
are lacking, the common consensus in 
current guidelines is that the use of an-
ticoagulant therapy in patients with LV 
thrombus after STEMI is reasonable (8). 
Failure to identify this finding, and sub-
sequently to prescribe anticoagulants, 
might imply catastrophic consequences 
such as stroke or peripheral embolism. 
On the other hand, in the era of a gen-
eralized use of dual antiplatelet ther-
apy, anticoagulants must be reserved 
for patients with definitive evidence of 
LV thrombus; an inadequate indication 
of anticoagulation in this context might 
unnecessarily boost the risk of bleeding. 
Consequently, the use of reliable car-
diac imaging tools is mandatory to make 
decisions in this field (13,14).
LGE has emerged as the refer-
ence technique for the diagnosis of LV 
thrombus. So far, to our knowledge, 
only three studies (2–4) have rigorously 
addressed the incidence of LV throm-
bus in STEMI using LGE and, in only 
two of them (3,4), the study group was 
exclusively made up of STEMI patients.
Weinsaft et al (2) reported, in a 
mixed cohort of 121 patients, an over-
all 20% incidence of LV thrombus. 
Table 2
Occurrence of Stroke, Hemorrhage Greater than BARC Type 2, and Peripheral 
Embolism in the Whole Study Group and Patients with and without LV Thrombus 
within the First 6 Months after STEMI
Characteristic All Patients
Patients with  
LV Thrombus
Patients without  
LV Thrombus P Value
No. of patients 392 27 365 …
Stroke 6 (1.5) 0 (0) 6 (1.6) .6
Hemorrhage . BARC type 2 1 (0.3) 1 (3.7) 0 (0) .07
Peripheral embolism 2 (0.5) 0 (0) 2 (0.5) .8
Stroke/hemorrhage/embolism 9 (2.3) 1 (3.7) 8 (2.2) .5
Note.—Data in parentheses are percentages.
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simultaneous anterior infarction and 
depressed LVEF. Moreover, whereas 
patients with these two characteristics 
displayed a considerable risk (20%) of 
LV thrombus, the risk in the remain-
ing categories (when only one or when 
none of these variables were present) 
was 1%22%.
The presence of simultaneous de-
pressed LVEF and anterior location im-
ply a larger infarct size, more blood sta-
sis, and a higher risk of thrombosis. The 
pathophysiologic basis underlying this 
association is obvious, but this simplic-
ity might be helpful in routine practice. 
It would be recommendable to keep in 
mind that this specific subgroup of pa-
tients (115 of 392, 29% in our series) 
is at significant risk (around 20%) of LV 
thrombus within the weeks and months 
following STEMI. A generalized use of 
anticoagulants in all patients with si-
multaneous anterior infarction and de-
pressed LVEF would be inappropriate: 
80% of them do not have LV thrombus. 
Thus, the use of sequential cardiac MR 
imaging in these cases seems reasonable.
Study Limitations
Nowadays, most patients do not un-
dergo cardiac MR imaging in the first 
week after STEMI. Consequently, it 
is unclear how many patients with un-
known LV thrombus not treated with an-
ticoagulants do or do not have stroke or 
embolism. Presumably the use of early 
reperfusion and dual antiplatelet therapy 
is markedly changing the natural history 
of this process. To know the exact bene-
fit derived from the use of anticoagulants 
in STEMI patients with LV thrombus de-
tected at cardiac MR imaging and man-
aged according to current recommenda-
tions, a large randomized multicenter 
study would be needed.
Due to the inherent limitations in 
the use of sequential cardiac MR im-
aging after STEMI, our series does not 
include the whole spectrum of post-
STEMI patients. Moreover, 182 of 574 
patients examined with cardiac MR im-
aging at 1 week did not undergo car-
diac MR imaging at 6 months. Lack of 
inclusion of all consecutive patients 1 
week and 6 months after STEMI could 
exert an influence on the incidence of 
thrombus: anterior infarction and the 
presence of a depressed (, 50%) LVEF. 
The majority of cases with LV throm-
bus (85%) took place in patients with 
benefit most from undergoing sequential 
cardiac MR imaging.
In our study, two factors emerged 
as simple and potent predictors of LV 
Table 3
Cardiac MR Characteristics at 1 Week in the Whole Study Group and Patients with and 
without LV Thrombus within the First 6 Months after STEMI
Characteristic All Patients
Patients with  
LV Thrombus
Patients without  
LV Thrombus P Value
No. of patients 392 27 365 …
LVEF (%)* 52 6 13 40 6 11 53 6 13 .001
LVEDVI (mL/m2)* 79 6 24 90 6 25 78 6 24 .001
LVESVI (mL/m2)* 39 6 21 55 6 22 38 6 20 .001
LV mass (g/m2)* 74 6 18 80 6 14 74 6 18 .001
Edema (% of LV mass)† 28 (17239) 39 (32253) 27 (16237) .001
MVO (% of LV mass)† 0 (022) 4.6 (0.3211) 0 (021.6) .001
Infarct size (% of LV mass)† 19 (10230) 33 (22247) 18 (9229) .001
Myocardial salvage index (%)† 23 (3242) 13 (2235) 23 (3244) .001
Note.—LVEDVI = LV end-diastolic volume index, LVESVI = LV end-systolic volume index, MVO = microvascular obstruction. The 
correlation coefficients among the eight cardiac MR characteristics are reported in Table E4 (online).
* Data are means 6 standard deviation
† Data are medians with 25th and 75th percentiles in parentheses.
Table 4
Multivariate Analysis of Potential Predictors of LV Thrombus within the First 6 Months 
after STEMI
Variable Odds Ratio* P Value
Killip class 1 … …
Killip class 2 versus 1 1.29 (0.37, 4.53) .7
Killip class 3 versus 1 0.88 (0.23, 56.32) .9
Killip class 4 versus 1 4.89 (0.93, 25.61) .1
Anterior infarction 7.38 (1.67, 32.65) .008
Time to reperfusion 0.99 (0.97, 1.01) .5
ST-segment resolution 1.00 (0.99, 1.01) .5
TIMI flow grade 3 after PCI … …
TIMI flow grade 2 versus 3 after PCI 2.0 (0.62, 6.37) .2
TIMI flow grade 1 versus 3 after PCI 0.99 (0.63, 59.32) .9
TIMI flow grade 0 versus 3 after PCI 5.69 (0.91, 27.62) .1
LVEF (%) 0.94 (0.90, 0.97) ,.001
LVEDVI (mL/m2) 1.01 (0.92, 1.11) .8
LVESVI (mL/m2) 0.99 (0.87, 1.13) .9
LV mass index (g/m2) 0.98 (0.95, 1.01) .3
LV mass with edema (mL/m2) 1.04 (0.99, 1.10) .1
MVO (% of LV mass) 1.08 (0.99, 1.18) .07
Infarct size (% of LV mass) 0.96 (0.91, 1.02) .2
Myocardial salvage index 0.99 (0.96, 1.04) .9
Note.—LVEDVI = LV end-diastolic volume index, LVESVI = LV end-systolic volume index, MVO = microvascular obstruction, 
TIMI = Thrombolysis in Myocardial Infarction, PCI = percutaneous coronary intervention. For the categorical variables, Killip class 
1 and TIMI flow grade 3 after PCI were considered as the normal reference values (8). Variables yielding P , .2 at univariate 
analyses (Tables 1 and 3) were tested.
* Data in parentheses are 95% confidence intervals.
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LV thrombus and on the occurrence of 
stroke, embolism, and hemorrhage.
For the purpose of this study, we 
used cardiac MR imaging 1 week and 
6 months after STEMI; in patients with 
persistent or newly detected LV throm-
bus at 6 months, cardiac MR imaging 
was repeated at 1 year. Although this 
strategy was effective and safe, the 
ideal timing for sequential cardiac MR 
imaging in this context is uncertain.
Conclusions
Cardiac MR imaging allows for an ex-
cellent characterization of the incidence 
and dynamics of LV thrombus after 
STEMI and, in this scenario, a strategy 
of anticoagulation therapy guided by 
means of cardiac MR imaging appears 
effective and safe. Patients with simul-
taneous anterior infarction and LVEF 
less than 50% are at highest risk of de-
veloping LV thrombus and, if available, 
the use of sequential cardiac MR im-
aging in this context seems reasonable.
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Figure 4
Figure 4: Graph shows incidence of LV thrombus ( VTh) depending on infarct location and the state of ejec-
tion fraction at 1-week cardiac MR imaging. The majority of cases with LV thrombus took place in the subset 
of patients with anterior infarction and LVEF less than 50% at 1-week cardiac MR imaging.
